Abstract
Background: Trichoderma reesei is known as a good
producer of industrial proteins but has hitherto been
less successful in the production of therapeutic
proteins. In order to elucidate the bottlenecks of
heterologous protein production, human a-galactosidase A
(GLA) was chosen as a model therapeutic protein. Fusion
partners were designed to compare the effects of
secretion using a cellobiohydrolase I (CBHI) carrier and
intracellular production using a gamma zein peptide from
maize (ZERA) which accumulates inside the endoplasmic
reticulum (ER). The two strategies were compared on the
basis of expression levels, purification performance,
enzymatic activity, bioreactor cultivations, and
transcriptional profiling.
Results: Constructs were cloned into the cbh1 locus of
the T. reesei strain Rut-C30. The secretion and
intracellular strains produced 20 mg/l and 636 mg/l of
GLA respectively. Purifications of secreted product were
accomplished using Step-Tactin affinity columns and for
intracellular product, a method was developed for
gravity-based density separation and protein body
solubilisation. The secreted protein had similar specific
activity to that of the commercially available mammalian
form. The intracellular version had 5-10-fold lower
activity due to the enzymes incompatibility with alkaline
pH. The secretion strain achieved 10% lower total biomass
than either the parental or the intracellular strain. The
patterns of gene induction for intracellular and parental
strains were similar, whereas the secretion strain had a
broader spectrum of gene expression level changes.
Identification of the genes involved indicated strong
secretion stress in the secretion strain and to a lesser
extent also in intracellular production. Genes involved
in the unfolded protein response (UPR) and ER-associated
degradation were induced by GLA production, including;
hac1, pdi1, prp1, cnx1, der1, and bap31.
Conclusions:Active human a-galactosidase could most
effectively be produced intracellularly in Trichoderma
reesei at >0.5 g/l by avoidance of the extracellular
environment, although purification was challenging due to
specific activity losses. Strain analysis revealed that
in addition to the issues with secreted proteases, the
processes of secretion stress including UPR and ER
degradation remain as bottlenecks for heterologous
protein production. Genetic engineering to eliminate
these bottlenecks is the logical path towards
establishing a strain capable of producing sensitive
heterologous proteins.
Original language | English |
---|---|
Article number | 91 |
Journal | BMC Biotechnology |
Volume | 14 |
DOIs | |
Publication status | Published - 2014 |
MoE publication type | A1 Journal article-refereed |
Keywords
- Therapeutic protein
- Human a-galactosidase A
- Trichoderma reesei
- Protein body